Menin is a scaffold protein that has been recognized for its role in T2DM as a key regulator of β-cell proliferation. Menin inhibition has previously been shown to improve glycemic control in diabetic mice. Herein, we report the first evidence that BMF-219, an orally bioavailable, selective, irreversible menin inhibitor, restores glycemic control in Zucker Diabetic Fatty (ZDF) Rat and Streptozotocin-induced Rat (STZ) models of T2DM. Rats were treated daily with BMF-219, vehicle, or pioglitazone for 16 days. BMF-2was well tolerated throughout the conduct of the study. BMF-2treatment resulted in a significant 50% reduction in fasting and non-fasting blood glucose levels, reduced serum insulin and c-peptide levels (p<0.05) , and reduced HOMA-IR (p<0.001) after two weeks of treatment in ZDF rats. BMF-2decreased glucose levels at all timepoints during an oral glucose tolerance test at Day 15 (AUC reduction of 54%, p<0.001) and at Day 29 (AUC reduction of 40%, p<0.05, ∼2 weeks after the last dose) in the ZDF model, indicating prolonged glycemic control. Strikingly, BMF-219, but not pioglitazone, reduced blood glucose levels during an OGTT in STZ animals (AUC reduction of 41%, p<0.05, see figure) . Significant reductions in blood lipemic levels (p<0.01) and body weight were observed in both models. Collectively, our data indicate the novel and marked potential of BMF-2as an oral, long-acting treatment for T2DM.


T. Butler: Employee; Biomea Fusion Inc. W. Li: None. B. Law: Stock/Shareholder; Biomea Fusion Inc., Mirum Pharmaceuticals. T. Archer: Employee; Biomea Fusion. T. Kinoshita: None. P. Somanath: Employee; Biomea Fusion, Inc. Stock/Shareholder; Biomea Fusion, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at